SAB Biotherapeutics(SABS) - 2023 Q3 - Quarterly Report

OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 (Mark One) For the transition period from ___________________ to ___________________ Commission File Number: 001-39871 (Exact Name of Registrant as Specified in its Charter) Delaware 85-3899721 (Sta ...